Dr Hornig’s talk in Sweden now available

Dr Mady Hornig, MD, Director of Translational Research at the Center for Infection and Immunity at Columbia University, made a presentation at the RME Sweden Severe ME conference in late October last year.  Dr Hornig went into more depth about her published cytokine work and described what her team is working on today.
Dr Hornig spoke about the crisis in funding, looking at gene expression and gene variants, screening for up to 1.7 million vertebrate viruses, metabolomics, and looking at how the immune system and the microbiome could affect metabolism and the brain.  She also spoke about the need to address the heterogeneity in ME/CFS in terms of symptomology but also illness duration and severity: the presence of sub-groups within the illness, each of which presents its own challenges and may require different treatment strategies.
Here is the full transcript of the talk, together with most of the slides.  Thanks to RME Sweden, it is also available to be viewed on YouTube.
 

Facebook
Twitter
WhatsApp
Email

Latest News

Blue square image with starbursts in the corners. the words, submit long covid drug recommendations to recover -tlc! are in the middle of the image, surrounded by thin white lines. the meaction logo is at the top of the image.

Submit Long COVID Drug Recommendations to RECOVER-TLC!

Last month, RECOVER TLC met at NIH headquarters in Bethesda. The goal was to initiate a drug development strategy for Long COVID clinical trials. Now, RECOVER TLC has opened the RECOVER-TLC Intervention Information Request Form, where you can make suggestions about which drugs and other interventions to trial!  Anyone can submit a therapeutic for consideration

Read More »
A classroom of people watching a panel discussion.

The RECOVER-Treating Long COVID (RECOVER TLC) The Path Forward

The RECOVER-Treating Long COVID (RECOVER TLC) Kick-off Meeting was Sept 23-25 in person and over Zoom. I had the privilege of attending over Zoom and Jaime Seltzer, #MEAction’s Scientific Director, represented the needs of the ME community in person and as an invited member of a panel on clinical trial design. There were many speakers

Read More »
Scroll to Top